Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

BackgroundSerum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments described to date and versatile tools for prot...

Full description

Bibliographic Details
Main Authors: Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, Emmanuel Goursaud, Karelle Ménochet, Jean van den Elsen, Richard J. Payne, Alastair D. G. Lawson, Anthony Scott-Tucker, Alex Macpherson
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1170357/full
Description
Summary:BackgroundSerum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments described to date and versatile tools for protein engineering.MethodsHere, we used phage display of bovine immune material to derive knob domains against human and rodent serum albumins. These were used to engineer bispecific Fab fragments, by using the framework III loop as a site for knob domain insertion. ResultsBy this route, neutralisation of the canonical antigen (TNFα) was retained but extended pharmacokinetics in-vivo were achieved through albumin binding. Structural characterisation revealed correct folding of the knob domain and identified broadly common but non-cross-reactive epitopes. Additionally, we show that these albumin binding knob domains can be chemically synthesised to achieve dual IL-17A neutralisation and albumin binding in a single chemical entity. ConclusionsThis study enables antibody and chemical engineering from bovine immune material, via an accessible discovery platform.
ISSN:1664-3224